<SEC-DOCUMENT>0001104659-21-124612-index.html : 20211008
<SEC-HEADER>0001104659-21-124612.hdr.sgml : 20211008
<ACCEPTANCE-DATETIME>20211008161437
ACCESSION NUMBER:		0001104659-21-124612
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20211008
DATE AS OF CHANGE:		20211008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nabriva Therapeutics plc
		CENTRAL INDEX KEY:			0001641640
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-260146
		FILM NUMBER:		211315456

	BUSINESS ADDRESS:	
		STREET 1:		25-28 NORTH WALL QUAY
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			D01 H104
		BUSINESS PHONE:		(610) 816-6640

	MAIL ADDRESS:	
		STREET 1:		414 COMMERCE DRIVE
		STREET 2:		STE 120
		CITY:			FORT WASHINGTON
		STATE:			PA
		ZIP:			19034

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nabriva Therapeutics AG
		DATE OF NAME CHANGE:	20150507
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>tm2129373-1_s1.htm
<DESCRIPTION>S-1
<TEXT>
Document 1 - file: tm2129373-1_s1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm2129373d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
Document 2 - file: tm2129373d2_ex5-1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>3
<FILENAME>tm2129373d2_ex10-43.htm
<DESCRIPTION>EXHIBIT 10.43
<TEXT>
Document 3 - file: tm2129373d2_ex10-43.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>tm2129373d2_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
Document 4 - file: tm2129373d2_ex23-1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>lg_nabriva-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 5 - file: lg_nabriva-4c.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2129373d2_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 6 - file: tm2129373d2_ex5-1img001.jpg

</DOCUMENT>
</SEC-DOCUMENT>